Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AML
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02474290 |
Recruitment Status :
Completed
First Posted : June 17, 2015
Last Update Posted : August 26, 2019
|
Sponsor:
Nanfang Hospital, Southern Medical University
Collaborators:
Peking University People's Hospital
Third Affiliated Hospital, Sun Yat-Sen University
Zhujiang Hospital
Xiangya Hospital of Central South University
First People's Hospital of Chenzhou
The First Affiliated Hospital of Guangzhou Medical University
Information provided by (Responsible Party):
Qifa Liu, Nanfang Hospital, Southern Medical University
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Completed |
---|---|
Actual Primary Completion Date : | July 21, 2018 |
Actual Study Completion Date : | August 10, 2019 |
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):